Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK9 | P50750 | 17/20 | 0.59 |
| ▸ | CCNT1 | O60563 | 11/20 | 0.59 |
| ▸ | CDK2 | P24941 | 3/20 | 0.55 |
| ▸ | CCNK | O75909 | 1/20 | 0.55 |
| ▸ | CDK14 | O94921 | 1/20 | 0.55 |
| ▸ | CDK1 | P06493 | 1/20 | 0.55 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.55 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.55 |
| ▸ | CDK16 | Q00536 | 1/20 | 0.55 |
| ▸ | CDK17 | Q00537 | 1/20 | 0.55 |
| ▸ | CDK18 | Q07002 | 1/20 | 0.55 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.55 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.53 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10285983 | 0.91 | CDK9 (0.56) | CDK9CCNT1 | |
| SCHEMBL1464191 | 0.89 | CDK9 (0.63) | CDK9CCNT1 | |
| SCHEMBL1462944 | 0.89 | CDK9 (0.61) | CDK9CCNT1 | |
| SCHEMBL10242904 | 0.87 | CDK9 (0.58) | CDK9 | |
| SCHEMBL1462005 | 0.85 | CCNT1 (0.77) | CDK9CCNT1 | |
| SCHEMBL1946423 | 0.85 | CDK9 (0.55) | CDK9CCNT1 | |
| SCHEMBL1947987 | 0.85 | CCNT1 (0.77) | CDK9CCNT1 | |
| SCHEMBL1949075 | 0.85 | CCNT1 (0.77) | CDK9CCNT1 | |
| SCHEMBL1946122 | 0.83 | CCNT1 (0.73) | CDK9CCNT1 | |
| SCHEMBL1946376 | 0.82 | CDK9 (0.64) | CDK9CCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110130380-A1 | Heteroaryl Kinase Inhibitors | NOVARTIS AG (CH) | 2011-06-02 | — | — | US | claimed |
| WO-2011026911-A1 | BIPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2011-03-10 | — | — | WO | claimed |
| EP-2473499-A1 | BIPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Novartis AG (CH) | 2012-07-11 | — | — | EP | disclosed |
| US-20110130380-A1 | Heteroaryl Kinase Inhibitors | NOVARTIS AG (CH) | 2011-06-02 | — | — | US | disclosed |
| US-20110130380-A1 | Heteroaryl Kinase Inhibitors | NOVARTIS AG (CH) | 2011-06-02 | — | — | US | disclosed |
| WO-2011026911-A1 | BIPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2011-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130380-A1 | Heteroaryl Kinase Inhibitors | CDK2, CDK1, CDKL1 | CDK9 5/4885CCNT1 47/4885CDK2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.